Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Bevacizumab Biosimilar as Adjuvant Therapy for Ruptured HCC
NCT07331883Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Ruijin Hospital. Started Nov 2025; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07331883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331883.